BLFS

BioLife Solutions Inc

BLFS, USA

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

https://www.biolifesolutions.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BLFS
stock
BLFS

BioLife Solutions' CFO Sells 30,000 Shares The Motley Fool

Read more →
BLFS
stock
BLFS

BioLife Solutions (NASDAQ:BLFS) Cut to “Hold” at Zacks Research Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$32.1

Analyst Picks

Strong Buy

7

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.36

Low 1

High 3

Return on Equity (ROE)

-

Very Low

0.18 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

0.16 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Medium

9.98 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.11

Low 1

High 0.3

Investors

* Institutions hold a combined 79.03% of the total shares of BioLife Solutions Inc

1.

Casdin Capital, LLC

(16.1119%)

since

2025/06/30

2.

BlackRock Inc

(11.5764%)

since

2025/06/30

3.

T. Rowe Price Investment Management,Inc.

(8.8778%)

since

2025/06/30

4.

Amvescap Plc.

(7.4857%)

since

2025/06/30

5.

Vanguard Group Inc

(6.0568%)

since

2025/06/30

6.

State Street Corp

(2.9454%)

since

2025/06/30

7.

Fred Alger Management, LLC

(2.609%)

since

2025/06/30

8.

Massachusetts Financial Services Company

(2.3039%)

since

2025/06/30

9.

Rockefeller Capital Management L.P.

(2.3007%)

since

2025/06/30

10.

Ameriprise Financial Inc

(2.2585%)

since

2025/06/30

11.

Dimensional Fund Advisors, Inc.

(2.0554%)

since

2025/06/30

12.

Geode Capital Management, LLC

(1.9256%)

since

2025/06/30

13.

Palisade Capital Management LLc

(1.9221%)

since

2025/06/30

14.

Geneva Capital Management

(1.8851%)

since

2025/06/30

15.

Royal Bank of Canada

(1.6543%)

since

2025/06/30

16.

ING Investment Management LLC

(1.5054%)

since

2025/06/30

17.

Cramer Rosenthal McGlynn LLC

(1.472%)

since

2025/06/30

18.

Bank of America Corp

(1.4043%)

since

2025/06/30

19.

Granahan Investment Management Inc..

(1.3446%)

since

2025/06/30

20.

Mutual Of America Capital Management LLC

(1.3345%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(5.5)
Net Net
Possible Net-Net(4)
Quality
Moderate Quality(5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.